Gene editing and cell therapy research by Caribou Biosciences
Caribou Biosciences prepares to attend Jefferies Global Healthcare Conference in New York
Caribou Biosciences announced its participation in the upcoming Jefferies Global Healthcare Conference in New York. The company will join leading industry players to discuss innovation in cell ...
Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat
Caribou Biosciences will be participating in the HCWCO 4th Annual BioConnect Investor Conference, offering an in-depth fireside chat featuring Chief Medical Officer Tina Albertson and Chief ...
Caribou Biosciences attends BioConnect Investor Conference in New York next week
Caribou Biosciences announced that it will participate in the 4th Annual BioConnect Investor Conference hosted by H.C. Wainwright in New York City next week. The event brings together leading ...
EHA2026 spotlights Caribou Biosciences advances in allogeneic CAR-T treatments for lymphoma and multiple myeloma
Caribou Biosciences announced that it will deliver two oral presentations at EHA2026 to reveal advancements in its allogeneic CAR-T cell therapy programs for blood cancers. The presentations will ...
Caribou Biosciences CEO Rachel Haurwitz to join Bank of America conference fireside chat
Caribou Biosciences is set to have its president and CEO, Rachel Haurwitz, PhD, participate in an upcoming fireside chat at the Bank of America Securities Health Care Conference. The discussion ...
Caribou Biosciences to participate in BofA Securities Health Care event in Las Vegas
Caribou Biosciences announced that its president and CEO, Rachel Haurwitz, PhD, will take part in a fireside chat at the BofA Securities Health Care Conference in Las Vegas next week. The ...
Caribou Biosciences receives FDA RMAT designation for CB-011 in multiple myeloma
Caribou Biosciences announced that the U.S. Food and Drug Administration has granted CB-011, its allogeneic cell therapy, the RMAT (Regenerative Medicine Advanced Therapy) designation for the ...
Caribou Biosciences announces Q4 and FY2025 financial results
Caribou Biosciences has announced its financial results for the fourth quarter and full fiscal year 2025. The company, which is active in cell therapy and gene editing, revealed the figures via ...
Caribou Biosciences CEO to address Evercore Healthcare Conference
Caribou Biosciences is set to participate in the 8th Annual Evercore Healthcare Conference. President and CEO, Rachel Haurwitz, PhD, will engage in a fireside chat. Attendees can expect insights ...
Caribou Biosciences signals access challenge in CAR-T cell therapy
Caribou Biosciences has raised concerns about the accessibility of CAR-T cell therapy for patients living significant distances from treatment centers. According to recent findings, patients ...
Caribou Biosciences reveals new data on CAR-T supply chain strategies
Caribou Biosciences is set to participate in the Advanced Therapies USA 2025 conference, where the company will reveal its latest data and insights on supply chain strategies for allogeneic CAR-T ...
